Multiple Sclerosis

Patients diagnosed with multiple sclerosis may develop depression as a result of the diagnosis but there is also research being done to show that depression can be part of the disease rather than as a result of it.

While the work being done to find a treatment for neuromyelitis optica is encouraging those in the field know they have not yet found a cure for the condition and that the agents being investigated will not help reverse the damage already done, which can be discouraging at times.

There are rare diseases and then there are ultra rare diseases. Neuromyelitis optica falls into the latter category but with a considerable amount of research behind it and a defined target to look at there has been success seen in finding treatments with more work being done every day.

While there are no approved treatments currently for neuromyelitis optica there is a considerable amount of work being done to help patients with this rare condition in the future.

At first glance, having patients with multiple sclerosis do yoga may seem unsafe and dangerous to their health. However, under the watch of a properly trained teacher and with careful monitoring this form of exercise has proven beneficial in even some of the most severe cases.

A recent study describes the first treatment that completely halts all detectable inflammatory activity in the central nervous system (CNS) in patients diagnosed with multiple sclerosis (MS) for a prolonged period and without the use of disease modifying drugs.

A treatment for multiple sclerosis may benefit patients with Parkinson's a study found.

Obstructive sleep apnea and sleep disturbances are linked to diminished cognitive ability in patients with multiple sclerosis.

Most patients are well-meaning and generally nice. But every now and then, you will get one who is a total pain to deal with. Maybe your patient lies to you, gets sarcastic, asks for special “favors,†or generally just pushes your buttons. We’ve all been there.

It is frustrating, to say the least, when your patients take their frustrations out on you. And, as if having to deal with an angry patient isn’t bad enough, providers now have to worry about the threat of legal action more than ever before.

Preventing relapses for patients with highly active multiple sclerosis is more easily accomplished with rituximab than with fingolimod.

Whether delivered intentionally or not, some physician comments are unhelpful at best and low-blows at worst. Saying certain things to patients can actually increase your risk of having a malpractice suit filed against you, making it especially important for you to always be mindful when speaking with patients.

It was not that long ago when doctors would sometimes not discuss the diagnosis of multiple sclerosis with their patients. Now not only is it a condition they can diagnose but treatment is also progressing by leaps and bounds.

Newly approved and longstanding treatment options are definitely an important part of the overall care picture but there is more work for a doctor to do beyond filling out a prescription pad.

As the treatment of relapsing remitting multiple sclerosis continues to add new treatment methods patients with progressive forms of the condition are still waiting for their first approved medication to manage their symptoms.

Acknowledging that uncertainty is a key factor in the care and treatment of multiple sclerosis is part of a solution to a problem, finding the best way to deal with that uncertainty is another issue that must be confronted by patients and doctors alike.

From the time a patient is diagnosed with multiple sclerosis there are often more questions than answers for extended periods of time. What that means for their care and management of symptoms is the subject of a recent study.

With a lot of the attention in multiple sclerosis care turning to finding treatments for progressive forms of the disease those who suffer relapses are in some ways being left in the shadows of treatment discoveries and care.

A recently concluded survey looked at issues most affecting patients with multiple sclerosis that they may not have been willing or able to discuss with health care providers but could help others with the condition in the future.

New medications are constantly being developed and approved for the treatment of multiple sclerosis. How those treatments are used and what the future holds for the disease remains to be seen.

There are known differences between men and women when it comes to multiple sclerosis and the likelihood of developing the disease. There are also differences in how best to treat patients given their gender.

In a chronic condition where depression is a known symptom treating the mental condition of a patient can be just as important as the physical aspects especially when suicide prevention is part of the overall care.

Defining what advanced disease means in multiple sclerosis is a topic open for discussion. Deciding a course of treatment after that determination is another challenge in overall patient care.

Even as the number of medications approved to treat relapsing remitting multiple sclerosis continues to grow patients with progressive forms of the condition still await the first approved treatment option to help manage their symptoms.

While it may not be possible to compare the efficacy of treatments for multiple sclerosis in clinical trials work is being done to look at the various options through results in actual practice.

Research into the inner workings of multiple sclerosis comes in all shapes and sizes including looking at specific parts of the brain. A recent study has looked at the role of the blood brain barrier and how it affects patients with this condition.

There are conferences held all over the world working to improve treatment of multiple sclerosis. The consortium of Multiple Sclerosis Centers is one that takes a different approach to this condition.

Individual trials have shown various benefits associated with fingolimod (Gilenya) for relapsing-remitted multiple sclerosis (RRMS), but its consistency across studies has not been fully understood.

Fingolimod (Gilenya) is an immunosuppressant used to treat multiple sclerosis, but improvements with disability have been unsteady with this drug.

Country music artist, Clay Walker – who is well-known for his hit songs “She Won’t Be Lonely Long†and “Live Until I Die" – was diagnosed with a relapsing form of multiple sclerosis (MS) at the age of 26.